Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06669572 · ClinicalTrials.gov registry record · Phase 2
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
A Phase 2 study of Carcinoma, Squamous Cell and Anorectal Cancer, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT06669572: Recruiting Phase 2 study of Carcinoma, Squamous Cell and Anorectal Cancer, sponsored by University of Chicago.
NCT06669572 is a Phase 2 study of Carcinoma, Squamous Cell and Anorectal Cancer that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 35 participants, below the 258-participant average among 14 other Carcinoma, Squamous Cell trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06669572, a Phase 2 study of Carcinoma, Squamous Cell and Anorectal Cancer, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to gather information on the safety and effectiveness of lenvatinib combined with pembrolizumab in anal/rectal cancer that has spread to other parts of the body and will not respond to standard care.
Primary Outcome
Number of participants who achieve a complete or partial response based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib
Study Locations (1)
Illinois
- University of Chicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-07-11 |
| Est. Completion | 2029-03-26 |
| Phase | Phase 2 |
What NCT06669572 shows while recruiting
NCT06669572 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 258-participant average among 14 other Carcinoma, Squamous Cell trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Carcinoma, Squamous Cell appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06669572 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06669572 about?
NCT06669572 is a clinical study titled "Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment". The purpose of this study is to gather information on the safety and effectiveness of lenvatinib combined with pembrolizumab in anal/rectal cancer that has spread to other parts of the body and will not respond to standard care.
What is the current status of trial NCT06669572?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-07-11. Estimated completion is 2029-03-26.
What conditions does trial NCT06669572 study?
This clinical trial studies the following conditions: Carcinoma, Squamous Cell, Anorectal Cancer.
What interventions are being tested in trial NCT06669572?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT06669572?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06669572 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Squamous Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06669572's enrollment target sits among peer trials
35 13th of 14 higher than 1 of 14 other Carcinoma, Squamous Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Squamous Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
ACTIVE NOT RECRUITING · Phase 2
-
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
ACTIVE NOT RECRUITING · Phase 2
-
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
COMPLETED · Phase 2
-
Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC
RECRUITING · Phase 1
-
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI